Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar portefeuille (99.75) Submitted: 12/15/2011 9:17:24 PM : Outperform Start Price: $21.19 ACOR Score: -8.94

There are currently 70 ACOR shares in my "fund" with break-even of around 8.18 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Featured Broker Partners


Advertisement